Literature DB >> 1117427

Mechanism of morphine-induced miosis in the dog.

H K Lee, S C Wang.   

Abstract

It was observed that dogs under 50 percent nitrous oxide and succinylcholine exhibited a moderately large pupil, maintained a good pupillary light reflex and had a relatively high sensitivity to the miotic effects of morphine. A cumulative dose of 1 mg/kg. i.v. of morphine caused marked and sustained miosis in these animals. Morphine, 1 mg, was found to have no pupillary effect by intraocular administration. Optic nerve section and cervical sympathectomy did not interfere with the miotic response in either acute or chronic preparations. Conversely, a cumulative i.v. dose of 30 mg/kg of morphine failed to cause pupillary constriction when oculomotor innervation had been interrupted. In addition, morphine, 0.2 to 0.6 mg/kg i.v., caused marked miosis in dogs whose occipital lobes or cerebral hemispheres had been removed. These findings suggest that morphine acts on a subcortical region causing constriction of the pupil. The possible location was ascertained by unit recording with microelectrodes. It was observed that pupilloconstrictor neurons in the visceral nuclei of the oculomotor nuclear complex responded to morphine, 0.2 mg/kg i.v., by increased frequency of discharge. Other neurons in the pupillary light reflex pathway showed depressed activity. Levallorphan, 0.05 mg/kg i.v., but not phenylephrine (locally applied to the conjunctival sac) antagonized all of the actions of morphine on the pupilloconstrictor neurons. The present findings demonstrate that the miosis induced by morphine is accomplished by an excitatory action of the narcotic on the visceral nuclei of the oculomotor nuclear complex.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1117427

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice.

Authors:  M Kaadan; A Stav; R Rabinowitz; S Shavit; A D Korczyn
Journal:  J Anesth       Date:  1994-09       Impact factor: 2.078

2.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  Sites and mechanisms of actions of enkephalin in the feline parasympathetic ganglion.

Authors:  Y Katayama; S Nishi
Journal:  J Physiol       Date:  1984-06       Impact factor: 5.182

Review 4.  The scientific basis for analgesic use in dentistry.

Authors:  E S Troullos; R D Freeman; R A Dionne
Journal:  Anesth Prog       Date:  1986 May-Jun

5.  The effects of naloxone on opiate and placebo analgesia in healthy volunteers.

Authors:  J Posner; C A Burke
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  The opiate addiction test: a clinical evaluation of a quick test for physical dependence on opiate drugs.

Authors:  H Ghodse; D R Taylor; J L Greaves; A J Britten; D Lynch
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice.

Authors:  A Stav; R Rabinowitz; A D Korczyn
Journal:  J Anesth       Date:  1992-10       Impact factor: 2.078

8.  Morphine eye-drops reduce homatropine induced mydriasis in man.

Authors:  M Fanciullacci; F Cangi; G Gatto; M Boccuni; U Pietrini
Journal:  Experientia       Date:  1984-07-15

9.  Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.

Authors:  Helmut Schmidt; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

10.  Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.

Authors:  James P Zacny; Kristen Wroblewski; Dennis W Coalson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.